Previous Close | 1.8100 |
Open | 1.8400 |
Bid | 1.7900 x 41800 |
Ask | 1.8600 x 40700 |
Day's Range | 1.7620 - 1.9500 |
52 Week Range | 1.0400 - 3.8200 |
Volume | |
Avg. Volume | 4,247,021 |
Market Cap | 732.278M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 925.00 |
EPS (TTM) | 0.0020 |
Earnings Date | Oct 27, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.33 |
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk with elevated triglycerides. Cardiovascular disease is a significant health issue for people li
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma Conference (February 13-16th, 2023; Virtual) Date/Time: February 14, 2023 10:40 a.m. ET Webcast: https://wsw.com/webcast/svb8/register.aspx?conf=svb8&page=amrn&url=https://wsw.com/webcast/svb8/am
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.